MX2021008558A - Metodo y sistema para la identificacion y cuantificacion de la fragmentacion de anticuerpos. - Google Patents

Metodo y sistema para la identificacion y cuantificacion de la fragmentacion de anticuerpos.

Info

Publication number
MX2021008558A
MX2021008558A MX2021008558A MX2021008558A MX2021008558A MX 2021008558 A MX2021008558 A MX 2021008558A MX 2021008558 A MX2021008558 A MX 2021008558A MX 2021008558 A MX2021008558 A MX 2021008558A MX 2021008558 A MX2021008558 A MX 2021008558A
Authority
MX
Mexico
Prior art keywords
identifying
fragments
antibody
mixed
molecular weight
Prior art date
Application number
MX2021008558A
Other languages
English (en)
Inventor
Shunhai Wang
Yuetian Yan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021008558A publication Critical patent/MX2021008558A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G01N30/724—Nebulising, aerosol formation or ionisation
    • G01N30/7266—Nebulising, aerosol formation or ionisation by electric field, e.g. electrospray
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Métodos para identificar y cuantificar fragmentos de anticuerpo e identificar el sitio de fragmentación de un anticuerpo en una muestra que comprende las etapas de cargar una muestra que incluye fragmentos del anticuerpo en un sistema cromatográfico que tiene una fase estacionaria (110) de exclusión por tamaño de modo mixto, lavar dicha fase estacionaria de exclusión por tamaño de modo mixto mediante el uso de una fase móvil para proporcionar un eluyente que comprende dichos fragmentos, determinar el peso molecular de dichos fragmentos mediante el uso de un espectrómetro de masas (120), y correlacionar dicho peso molecular con estándares proteicos conocidos.
MX2021008558A 2019-01-16 2020-01-15 Metodo y sistema para la identificacion y cuantificacion de la fragmentacion de anticuerpos. MX2021008558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962793004P 2019-01-16 2019-01-16
PCT/US2020/013648 WO2020150328A1 (en) 2019-01-16 2020-01-15 Method and system of identifying and quantifying antibody fragmentation

Publications (1)

Publication Number Publication Date
MX2021008558A true MX2021008558A (es) 2021-08-19

Family

ID=69529055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008558A MX2021008558A (es) 2019-01-16 2020-01-15 Metodo y sistema para la identificacion y cuantificacion de la fragmentacion de anticuerpos.

Country Status (13)

Country Link
US (2) US11486864B2 (es)
EP (1) EP3911947A1 (es)
JP (1) JP2022517338A (es)
KR (1) KR20210116502A (es)
CN (1) CN113227785A (es)
AU (1) AU2020208360A1 (es)
BR (1) BR112021011194A2 (es)
CA (1) CA3123052A1 (es)
EA (1) EA202191961A1 (es)
IL (1) IL284637A (es)
MX (1) MX2021008558A (es)
SG (1) SG11202106370WA (es)
WO (1) WO2020150328A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385239B2 (en) * 2018-10-31 2022-07-12 Regeneran Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
AU2021286463A1 (en) * 2020-06-09 2022-12-22 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies
US20230018713A1 (en) * 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493817A1 (en) * 2002-08-06 2004-02-12 The John Hopkins University Use of biomarkers for detecting ovarian cancer
WO2007038523A2 (en) * 2005-09-27 2007-04-05 Center For Applied Proteomics And Molecular Medicine Method of isolating analytes from a sample
MX2015006868A (es) * 2012-11-30 2015-10-05 Novartis Ag Metodos para la elaboracion de conjugados a partir de proteinas que contienen disulfuro.
US11092574B2 (en) 2013-12-24 2021-08-17 Waters Technologies Corporation Materials for hydrophilic interaction chromatography and processes for preparation and use thereof for analysis of glycoproteins and glycopeptides
WO2016018978A1 (en) 2014-07-29 2016-02-04 Mayo Foundation For Medical Education And Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
CA3013340A1 (en) * 2016-02-04 2017-08-10 Oncobiologics, Inc. Methods for identifying and analyzing amino acid sequences of proteins
MX2019000935A (es) * 2016-08-16 2019-07-04 Regeneron Pharma Metodos para cuantificar anticuerpos individuales de una mezcla.
US11385239B2 (en) * 2018-10-31 2022-07-12 Regeneran Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein

Also Published As

Publication number Publication date
BR112021011194A2 (pt) 2021-08-31
KR20210116502A (ko) 2021-09-27
US20200225199A1 (en) 2020-07-16
US20230314388A1 (en) 2023-10-05
US12000811B2 (en) 2024-06-04
US11486864B2 (en) 2022-11-01
CA3123052A1 (en) 2020-07-23
EP3911947A1 (en) 2021-11-24
CN113227785A (zh) 2021-08-06
IL284637A (en) 2021-08-31
AU2020208360A1 (en) 2021-07-01
EA202191961A1 (ru) 2021-12-13
JP2022517338A (ja) 2022-03-08
SG11202106370WA (en) 2021-07-29
WO2020150328A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
MX2021008558A (es) Metodo y sistema para la identificacion y cuantificacion de la fragmentacion de anticuerpos.
ATE529752T1 (de) Antikörperquantifizierung
Lam et al. Online coupling of reverse-phase and hydrophilic interaction liquid chromatography for protein and glycoprotein characterization
DE602004018388D1 (de) Proteinphosphorylierung bei grosszellig-anaplastischem lymphom
WO2002025287A8 (en) Detection of peptides
WO2008005455A3 (en) Peptide antibody depletion and its application to mass spectrometry sample preparation
WO2004031730A3 (en) High sensitivity quantitation of peptides by mass spectrometry
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
WO2005088303A3 (en) Identification and characterization of proteins using new database search modes
Schoenherr et al. Anti-Peptide Monoclonal Antibodies Generated for Immuno-Multiple Reaction Monitoring-Mass Spectrometry Assays Have a High Probability of Supporting Western blot and ELISA*[S]
JP2019507341A5 (es)
SG127861A1 (en) in situ biomarker identification
MX2021008791A (es) Cromatografia de proteina a - espectrometro de masas de ionizacion por electrospray.
Martínez‐Esteso et al. Label‐free proteomic analysis of wheat gluten proteins and their immunoreactivity to ELISA antibodies
MX2021009267A (es) Analisis ce-ms de microfluidos naturales de la heterogeneidad de la carga de anticuerpos.
DK0960336T3 (da) Peptidreagens til påvisning af humant cytomelagovirus (CMV)
AU2174002A (en) Method for analyzing proteins
Léger et al. Solid-phase hexapeptide ligand libraries open up new perspectives in the discovery of biomarkers in human plasma
AU2017342043A8 (en) Method for the detection of Apolipoprotein E4
EP3739338A3 (en) Methods for predicting immunotherapy response of subject having cancer
Reichel Identification of zinc‐alpha‐2‐glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano‐HPLC and high‐resolution high‐mass accuracy ESI‐MS/MS
Saito et al. Establishment and application of a high-quality comparative analysis strategy for the discovery and small-scale validation of low-abundance biomarker peptides in serum based on an optimized novel peptide extraction method
Liu et al. LysargiNase enhances protein identification on the basis of trypsin on formalin‐fixed paraffin‐embedded samples
WO2006034335A3 (en) Method of detecting cancer based on immune reaction to boris
Korbakis et al. Delineating monoclonal antibody specificity by mass spectrometry